| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
11,532 |
9,818 |
$558K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
1,785 |
1,502 |
$151K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
1,636 |
1,371 |
$125K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
1,401 |
1,207 |
$109K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
1,208 |
1,153 |
$52K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
1,434 |
1,336 |
$49K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
1,720 |
1,621 |
$44K |
| 92587 |
|
3,088 |
2,512 |
$40K |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
509 |
399 |
$39K |
| 92015 |
Determination of refractive state |
2,082 |
1,855 |
$37K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
1,379 |
1,267 |
$20K |
| 90651 |
|
636 |
507 |
$13K |
| 96110 |
Developmental screening, with scoring and documentation, per standardized instrument |
729 |
640 |
$12K |
| 36415 |
Collection of venous blood by venipuncture |
2,614 |
2,073 |
$11K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
204 |
199 |
$10K |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
133 |
108 |
$9K |
| 90686 |
|
790 |
689 |
$8K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
385 |
363 |
$8K |
| 90734 |
|
538 |
420 |
$8K |
| 90620 |
|
276 |
219 |
$5K |
| 0071A |
|
84 |
81 |
$4K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
254 |
177 |
$4K |
| 86580 |
|
653 |
560 |
$3K |
| 0072A |
|
65 |
61 |
$3K |
| 0001A |
|
56 |
53 |
$2K |
| 90621 |
|
112 |
80 |
$2K |
| 90715 |
|
149 |
126 |
$2K |
| 90658 |
|
217 |
183 |
$2K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
40 |
39 |
$1K |
| 90670 |
|
87 |
68 |
$1K |
| 90744 |
|
84 |
79 |
$661.27 |
| 90700 |
|
47 |
43 |
$646.07 |
| 83655 |
|
52 |
40 |
$617.31 |
| 0003A |
|
12 |
12 |
$518.34 |
| 90672 |
|
67 |
51 |
$422.40 |
| 90707 |
|
29 |
25 |
$395.54 |
| 99422 |
|
15 |
15 |
$379.96 |
| 90633 |
|
28 |
26 |
$349.20 |
| 91300 |
|
65 |
61 |
$277.73 |
| 90713 |
|
16 |
15 |
$271.56 |
| 90647 |
|
15 |
12 |
$248.18 |
| 85018 |
|
55 |
50 |
$124.24 |
| 90716 |
|
14 |
12 |
$76.80 |
| 91307 |
|
92 |
92 |
$30.22 |
| J7620 |
Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme |
117 |
73 |
$13.72 |